ArticleBMC cancer2026
Prognostic value of diffusely increased FDG uptake in spleen and/ or bone marrow due to reticuloendothelial system activation in lymphoma patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Primary Tumor and Immune Organ Metabolic Parameters Derived from PretreatmentMolecular imaging and radionuclide therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe primary objective of this investigation was to evaluate the predictive utility of diffusely increased
methodsOur retrospective cohort comprised 629 treatment-naïve lymphoma patients with pathological confirmation who received diagnostic 18 F-FDG PET/CT scans between June 2018 and December 2024. The patients cohort with conditions affecting splenic/bone marrow metabolism (e.g., anemia) or focal uptake were excluded, leaving 142 patients. Based on liver uptake, spleen and bone marrow FDG uptake were classified into two groups: diffusely increased FDG uptake (dFDG, n = 67) and normal FDG uptake (nFDG, n = 75). Hematologic parameters (white blood cells, monocytes, neutrophils, platelets) and inflammatory markers (lactate dehydrogenase [LDH], β
resultsNo statistically significant differences were observed in age, sex, or B symptoms between groups. The dFDG group had more advanced staging (Stage III/IV: 83.6% vs. 52.0%, p < 0.001) and significantly higher inflammatory markers (LDH, β
conclusionDiffuse splenic FDG uptake strongly correlates with systemic inflammation. The SLR emerged as an independent predictor of progression-free survival in our lymphoma cohort. Diffuse bone marrow uptake may involve non-neoplastic factors and requires comprehensive clinicopathological assessment. This study provides new evidence for PET/CT-guided prognostic evaluation in lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.